Opus Genetics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2013 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.2M | $11.0M | $19.0M | $39.9M | $589.0K | $0 | $3.0M | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | $5.5M | $3.3M |
| SG&A Expense | $22.0M | $18.2M | $12.0M | $7.3M | $8.1M | $2.8M | $1.8M | $4.7M |
| Operating Income | $-38.6M | $-62.1M | $-10.6M | $18.2M | $-22.7M | $-20.0M | $-4.2M | $-8.0M |
| Operating Margin | -271.9% | -564.7% | -55.5% | 45.7% | -3,854.8% | — | -139.8% | — |
| Interest Expense | — | — | $0 | $9.0K | $2.0K | $6.8M | $1.4M | — |
| Pretax Income | $-49.6M | $-57.5M | $-10.0M | $18.2M | $-56.7M | $-24.6M | $-6.2M | — |
| Income Tax Expense | $0 | $0 | $12.0K | $315.0K | $0 | $0 | $0 | $0 |
| Net Income | $-49.6M | $-57.5M | $-10.0M | $17.9M | $-56.7M | $-24.6M | $-6.2M | $-9.5M |
| Net Margin | -349.3% | -523.4% | -52.4% | 44.9% | -9,625.3% | — | -205.6% | — |
| EPS (Basic) | $-0.80 | $-1.08 | $-0.23 | $0.45 | $-1.91 | $-0.88 | $-0.36 | $-0.01 |
| EPS (Diluted) | $-0.80 | $-1.08 | $-0.23 | $0.44 | $-1.91 | $-0.88 | $-0.36 | $-0.01 |
| Shares Outstanding (Basic) | 62.2M | 53.4M | 43.2M | 39.9M | 29.7M | 28.0M | 17.1M | 880.3M |
| Shares Outstanding (Diluted) | 62.2M | 53.4M | 43.2M | 41.2M | 29.7M | 28.0M | 17.1M | 880.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |